Published: 2019 April 09

Enzyme-Linked Immunosorbent Assay Market

SKU : BT888
180 pages
Report Summary
Table of Contents

Enzyme Linked Immunosorbent Assay Market Segmented By Test Type(Sandwich ELISA, Indirect ELISA, Multiple and portable ELISA, Competitive ELISA), By Application(Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantification), By End-user(Hospitals, Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2022-2029

Enzyme Linked Immunosorbent Assay Market is expected to grow at a high CAGR of 9% during the forecasting period (2022-2029). Enzyme-Linked Immunosorbent Assay (ELISA) is a plate-based assay technique designed for detecting and quantifying substances such as proteins, peptides, antibodies, and hormones. The ELISA is used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as quality control, check-in various industries. ELISA is a biochemical reaction in which an antigen from the sample is attached to a surface and then complexed with an antibody that is linked to an enzyme.

The reaction produces a detectable signal, most commonly a color change in the substrate which is highly specific to the antibody-antigen interaction. The conventional diagnostic applications of ELISA are pregnancy tests, HIV infection, and the measurement of soluble proteins, cytokines, and others.

Enzyme Linked Immunosorbent Assay Market Drivers and Restraints:

  • Global Enzyme-Linked Immunosorbent Assay (ELISA) market is primarily driven by the increasing incidence of chronic diseases such as infectious diseases, vector-borne diseases, and cancer.

  • Moreover, laboratory automation for ELISA assay and the emergence of cost-effective technologies are other factors aiding the growth of ELISA market. For instance, the National Cancer Institute (NCI), 2016 reported approximately 1.7 million new cases of cancer were diagnosed in the U.S. alone.

  • The increasing R&D on biomarkers and monoclonal antibodies coupled with the continued growth of the drug discovery market owing to the demand for accurate and early diagnosis of disease along with the rising geriatric population are some more major driving factors for the ELISA market.

  • However, the threat of substitution due to the availability of other immunoassays and new technologies such as the multiplex proteomic array platform can hinder or may limit the growth of the market.

Enzyme Linked Immunosorbent Assay Market Segmentation

  • By test type, the global enzyme-linked immunosorbent assay (ELISA) market is segmented into sandwich ELISA, multiple and portable ELISA, indirect ELISA, and competitive ELISA. Indirect ELISA segment of the market is projected to be the fastest-growing share.

  • This testing method is mainly used for measuring antibodies in almost all human infections. Therefore with the high prevalence of infectious disease and vector-borne diseases such as dengue, yellow fever, and malaria drive this market share.

  • For instance, the World Health Organization (WHO) stated that more than 2.5 billion people of the world’s population are now at risk of dengue and estimates there may be more than 100 million dengue infections worldwide every year.

  • By the application, the ELISA market is segmented into immunology, inflammation, infectious diseases, cancer, protein quantification, and others. The immunology market share dominates this market segment regarding revenue owing to the high sensitivity and specificity of the ELISA test and its ability to do a large number of tests simultaneously.

Geographical Share

  • Regarding region, North America dominates the global Enzyme-Linked Immunosorbent Assay (ELISA), Market. It can be attributed to the development of innovative products by manufacturers in the region.

  • Moreover, the commercializing of various private and public sectors research inventions and collaborating with existing market players to carry out the development in Immunoassay-based clinical diagnostics are expanding the region’s share in the ELISA market.

  • For instance, in March 2018, BARD1 Life Sciences, a U.S-based Company, is expected to commercialize its BARD1-Ovarian blood-based ELISA test which is used to identify ovarian cancer in early stages.

  • The company entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system. It includes the transfer of the current BARD1 assay design to Thermo Fisher for optimization using Thermo Fisher’a ProcartaPlex Technology for BARD1’s research use.

  • Furthermore, Asia Pacific is projected to be the fastest-growing region in ELISA market, owing to the geographical expansion of regional and international players along with the introduction of enzyme-based test kits at affordable prices.

  • For instance, in January 2019, AroCell AB announced that a distribution agreement had been signed with the Beijing-based company Gongyingshi for the promotion and distribution of the AroCell TK 210 ELISA in China.

Competitive Trends

  • Several companies have adopted collaborations and used new product launches to help them to stand out as strong competitors in the market and also expand their sales in the global ELISA market.

  • January 2019, New ELISA blood test, sclera-smart, from Gemelli Biotech measures levels of anti-vinculin, recently found to be elevated in patients with scleroderma and associated with gastrointestinal complications.

  • It suggests a link between scleroderma and the gut microbiome, a finding that could open the door to discoveries of new microbiome-related therapeutic and diagnostic tools for scleroderma.

  • October 2018, The U.S. Food and Drug Administration (FDA) approved the marketing of the PicoAMH Elisa diagnostic test (determine women’s menopausal status) to Ansh Labs, a developer, and manufacturer of immunoassay reagent test kits used to advance target discovery, therapeutic development, biomedical research, and clinical diagnostics.

  • The company will market its Anti-Müllerian (AMH) assay kit, picoAMH, under the trademark MenoCheck.

  • In May 2017, ALPCO launched new ELISA products, gastrointestinal and inflammatory bowel disease (IBD) assays. They are the Zonulin Stool ELISA and Zonulin Serum ELISA and aid in the study of gut permeability and celiac disease.

Trending Topics

Immuno Oncology Assays Market

Immunology Drugs Market

Immunoprotein Diagnostic Testing Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy